Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC)

被引：0
|
作者：
Passalacqua, R.
Buzio, C.
Buti, S.
Labianca, R.
Porta, C.
Boni, C.
Rondini, E.
Camisa, R.
Sabbatini, R.
Artioli, F.
Caminiti, C.
机构：
[1] Ist Ospitalieri, Cremona, Italy
[2] Univ Parma, Parma, Italy
[3] Bergamo Hosp, Bergamo, Italy
[4] Policlin San Matteo, Pavia, Italy
[5] Arcispedale S Maria Nuova, Reggio Emilia, Italy
[6] Univ Hosp, Parma, Italy
[7] Univ Hosp, Modena, Italy
[8] Hosp Carpi, Carpi, MO, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA5028
引用
收藏
页数：1
相关论文
共 42 条
  • [21] Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma
    Gollob, Jared A.
    Sciambi, Catherine J.
    Peterson, Bercedis L.
    Richmond, Tina
    Thoreson, Monica
    Moran, Kelly
    Dressman, Holly K.
    Jelinek, Jaroslav
    Issa, Jean-Pierre J.
    CLINICAL CANCER RESEARCH, 2006, 12 (15) : 4619 - 4627
  • [22] A randomized, prospective, Phase 2 study, with Sorafenib (So) and Interleukin-2 (IL-2) versus So alone as first line treatment in advanced Renal Cell Cancer (RCC): ROSORC Trial
    Procopio, G.
    Verzoni, E.
    Bracarda, S.
    Ricci, S.
    Miceli, R.
    Bertolini, A.
    Porta, C.
    Ridolfi, R.
    Zilembo, N.
    Bajetta, E.
    EJC SUPPLEMENTS, 2009, 7 (02): : 425 - 425
  • [23] A RANDOMIZED, PROSPECTIVE, PHASE 2 STUDY, WITH SORAFENIB (S) AND INTERLEUKIN-2 (IL-2) VERSUS S ALONE AS FIRST LINE TREATMENT IN ADVANCED RENAL CELL CANCER (RCC): ROSORC TRIAL
    Procopio, Giuseppe
    Verzoni, Elena
    Bracarda, Sergio
    Ricci, Sergio
    Bregni, Marco
    Conti, Giario N.
    Amoroso, Vito
    Sacco, Cosimo
    Zilembo, Nicoletta
    Bajetta, Emilio
    ANNALS OF ONCOLOGY, 2009, 20
  • [24] Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase II trial
    Buti, S.
    Lazzarelli, S.
    Simonelli, C.
    Venturini, S.
    Spazzapan, S.
    Lo Re, G.
    Mattioli, R.
    Chiesa, M. Dalla
    Brighenti, M.
    Passalacqua, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Subcutaneous (sc) interleukin-2 (IL-2) plus alpha-interferon (IFNα) in out-patients (pts) with metastatic renal cell carcinoma (MRCC).: SCAPP III trial.
    Tourani, JM
    Pfister, C
    Tubiana, N
    Rixe, O
    Benoit, G
    Mayeur, D
    Lucas, V
    Prevot, G
    Untereiner, M
    Favre, R
    ANNALS OF ONCOLOGY, 2000, 11 : 75 - 75
  • [26] Multicenter phase trial of out-patient therapy with sequential low-dose interferon-γ-1b and interleukin-2 in advanced renal cell carcinoma
    Djavanmard, MP
    Kramer, G
    Steger, GG
    Zielinski, C
    Marberger, M
    JOURNAL OF UROLOGY, 1998, 159 (05): : 197 - 197
  • [27] Randomized Italian multicentric trial comparing cisplatinum and gemcitabine with or without low dose interleukin-2 (IL-2) in advanced non-small cell lung cancer (NSCLC).
    Ridolfi, R
    Dall'agata, M
    Bertetto, O
    Santo, A
    Naglieri, E
    Lopez, M
    Recchia, F
    Lissom, P
    Porcile, G
    Fumagalli, L
    Nanni, O
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 655S - 655S
  • [28] A randomized phase II trial of interleukin-2/interferon-α plus bevacizumab versus interleukin-2/interferon-α in metastatic renal cell carcinoma (mRCC): Results from the Danish Renal Cancer Group (DARENCA) study 1
    Donskov, Frede
    Jensen, Niels Viggo
    Smidt-Hansen, Torben
    Brondum, Line
    Geertsen, Paul F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] A randomized phase II trial of interleukin-2 and interferon- plus bevacizumab versus interleukin-2 and interferon- in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1
    Donskov, Frede
    Jensen, Niels Viggo
    Smidt-Hansen, Torben
    Brondum, Line
    Geertsen, Poul
    ACTA ONCOLOGICA, 2018, 57 (05) : 589 - 594
  • [30] A PHASE-I STUDY OF PROLONGED CONTINUOUS INFUSION OF LOW-DOSE RECOMBINANT INTERLEUKIN-2 IN MELANOMA AND RENAL-CELL CANCER .1. CLINICAL ASPECTS
    VLASVELD, LT
    RANKIN, EM
    HEKMAN, A
    RODENHUIS, S
    BEIJNEN, JH
    HILTON, AM
    DUBBELMAN, AC
    VYTHDREESE, FA
    MELIEF, CJM
    BRITISH JOURNAL OF CANCER, 1992, 65 (05) : 744 - 750
12345